World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
94
Citations
42154
World Ranking
10312
National Ranking
23

Overview

John Crown is affiliated with Dublin City University in Ireland and has contributed extensively to the fields of Medicine and Biochemistry, Genetics and Molecular Biology. Their research output demonstrates a strong focus on oncology and related biomedical sciences.

The main fields of study covered by Crown include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Within these broader fields, Crown's work is concentrated in several subfields, particularly:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Molecular Biology
  • Cancer Research
  • Radiology, Nuclear Medicine and Imaging

The research topics that feature prominently in Crown's publications are:

  • HER2/EGFR in Cancer Research
  • Advanced Breast Cancer Therapies
  • Cancer Immunotherapy and Biomarkers
  • Breast Cancer Treatment Studies
  • Cancer Treatment and Pharmacology
  • Cancer Genomics and Diagnostics
  • Monoclonal and Polyclonal Antibodies Research

John Crown has collaborated frequently with several co-authors, notably:

  • Denis M. Collins
  • Alex J. Eustace
  • Bryan T. Hennessy
  • Janice M. Walshe
  • Neil T. Conlon

Their published work appears regularly in a range of scientific venues, with the most frequent being:

  • Cancer Research
  • Journal of Clinical Oncology
  • Annals of Oncology
  • Breast Cancer Research and Treatment
  • Investigational New Drugs

Several recent papers provide insight into Crown's research emphasis and collaborations. Notable papers include:

  • "Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial" (2020), published in The Lancet
  • "Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial" (2020), Journal of Clinical Oncology
  • "MYC as a target for cancer treatment" (2021), Cancer Treatment Reviews
  • "Targeting p53 for the treatment of cancer" (2020), Seminars in Cancer Biology
  • "Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13,864 women in seven randomised trials" (2021), The Lancet Oncology

Best Publications

  • Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

    Charles E. Geyer;John Forster;Deborah Lindquist;Stephen Chan

  • Adjuvant trastuzumab in HER2-positive breast cancer.

    Dennis Slamon;Wolfgang Eiermann;Nicholas Robert;Tadeusz Pienkowski

  • Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

    Gunter Von Minckwitz;Chiun Sheng Huang;Max S. Mano;Sibylle Loibl

  • The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

    Richard S Finn;John P Crown;Istvan Lang;Katalin Boer

  • Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98

    Sherene Loi;Nicolas Sirtaine;Fanny Piette;Roberto Salgado

  • A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

    David Cameron;Michelle Casey;Michael Press;Deborah Lindquist

  • Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study.

    D. Slamon;W. Eiermann;N. Robert;T. Pienkowski

  • Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer

    Stephen Chan;Kay Friedrichs;Daniel Noel;Tamàs Pintér

  • Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis

    Colin Clarke;Stephen F. Madden;Padraig Doolan;Sinead T. Aherne

  • The taxanes: an update

    John Crown;Michael O'Leary

  • Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes.

    Claire Corcoran;Sweta Rani;Keith O’Brien;Amanda O’Neill

  • Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With >= 2 HER2-Directed Regimens: Phase III NALA Trial

    Cristina Saura;Mafalda Oliveira;Yin-Hsun Feng;Ming-Shen Dai

  • Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer

    B. Corkery;J. Crown;M. Clynes;N. O'Donovan

  • Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.

    Neil A. O'Brien;Brigid C. Browne;Lucy Chow;Yuhua Wang

  • Mutant p53 as a target for cancer treatment.

    Michael J. Duffy;Naoise C. Synnott;John Crown

  • Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer

    Mark D. Pegram;Tadeusz Pienkowski;Donald W. Northfelt;Wolfgang Eiermann

  • NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+

    Louis Fehrenbacher;Reena S. Cecchini;Charles E. Geyer;Priya Rastogi

  • Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens

    Vicente Valero;John Forbes;Mark D. Pegram;Tadeusz Pienkowski

  • Docetaxel and Paclitaxel in the Treatment of Breast Cancer: A Review of Clinical Experience

    John Crown;Michael O’Leary;Wei-Seong Ooi

  • Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response.

    A D Seidman;B S Reichman;J P Crown;T J Yao

Frequent Co-Authors

Michael J. Duffy
Michael J. Duffy University College Dublin
Martin Clynes
Martin Clynes Dublin City University
Bryan T. Hennessy
Bryan T. Hennessy Beaumont Hospital
Larry Norton
Larry Norton Memorial Sloan Kettering Cancer Center
Richard S. Finn
Richard S. Finn University of California, Los Angeles
Kenneth J. O'Byrne
Kenneth J. O'Byrne Queensland University of Technology
John R. Mackey
John R. Mackey University of Alberta
Marc Buyse
Marc Buyse Hasselt University
Angelo Di Leo
Angelo Di Leo Academy for Urban School Leadership
Michael F. Press
Michael F. Press University of Southern California

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're considering studying medicine in the USA, there are several related online degree options and career pathways to explore. Many students choose to start with specialized healthcare fields that offer flexible and affordable online programs.

Health information management is a rapidly growing area, and enrolling in rhit programs online can prepare you for roles that manage crucial medical data. Another increasingly popular choice is completing medical billing and coding online, which opens up administrative positions in hospitals, clinics, and insurance companies.

For those aiming for clinical work, nurse practitioner programs provide advanced training to deliver patient care at a higher level. If you're looking for a more accessible entry point, there are many cheapest online nursing programs that lead to RN licensure or other nursing roles while allowing you to study at your own pace.

These online healthcare programs can serve as a stepping stone towards a future medical degree or help jumpstart a rewarding healthcare career.

Best Scientists Citing John Crown

Trending Scientists

Recently Published Articles